VACCINES

MenQuadfi^™ Overview

MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y.

Before you prescribe this vaccine please refer to the Prescribing information and SmPC links below.

MenQuadfi^™ Prescribing information

View the MenQuadfi^™ SmPC

Why help protect your patients with MenQuadfi?

Invasive meningococcal disease (IMD) is associated with a significant risk of death and severe sequelae. 50% of IMD cases are fatal if left untreated and even when the disease is diagnosed and treated early, 8-15% IMD patients will die. Sequelae such as neurological and hearing impairment or amputation occur in up to 20% of survivors.^1,2

IMD remains a serious threat in the UK and abroad. In the meningitis belt of sub Saharan Africa, seasonal hyperendemicity is observed every dry season with weekly incidence rates rising to up to 10/100,000 population.^3,4 IMD epidemics have also been linked to Islamic pilgrimages to Makkah, resulting in importations of IMD to the UK. ⁵ Globally, specific serogroups can shift unpredictably within regions over time.^6-9

MenQuadfi is designed to help protect individuals aged 12 months and older against IMD caused by serogroups A, C, W and Y.

It is the only MenACWY conjugate vaccine in Europe available in a fully liquid formulation.^10,11 This can potentially save time and reduce reconstitution errors.¹²

MenQuadfi uses a tetanus toxoid carrier protein, which is able to impact the
T-cell dependant immune system.¹³

High seroprotection has been demonstrated with MenQuadfi across all licensed age groups and all 4 serogroups (A,C,W,Y). In clinical trials, the safety of MenQuadfi was shown to be similar to comparator vaccines.^14-17

A MenACWY certificate will be provided on ordering MenQuadfi

 

	Presentation	Schedule	Further doses	Age range
	1 single dose vial (0.5mL)	1 dose	A single 0.5mL dose may be used to boost subjects who have previously received a meningococcal vaccine containing the same serogroups.	12 months+

 

References:

1. WHO. Meningococcal meningitis. https://www.who.int/news room/fact sheets/detail/meningococcal meningitis. Updated 19 February 2018 [Accessed September 2021].
2. European Centre for Disease Prevention and Control. Factsheet about meningococcal disease. Last updated 2019. Accessible from: https://www.ecdc.europa.eu/en/meningococcal disease/factsheet [Accessed September 2021].
3. W. Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483 498. doi:10.1016/j.jinf.2020.05.079.
4. TravelHeallthPro . Meningococcal Disease. 2020. Accessible from: https://travelhealthpro.org.uk/factsheet/42/meningococcal disease [Accessed September 2021].
5. Public Health England. Green Book Chapter 22: Meningococcal. 2016. [Accessed September 2021].
6. Presa J, Findlow J, Vojicic J, Williams S, Serra L. Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY TT Vaccine: A Review. Infect Dis Ther . 2019;8(3):307 333.
7. National Reference Laboratory. National Institute of Public Health. Czech Republic. Czech Republic epidemiology data table. httP //www.szu.cz/tema/prevence/meningokokove infekce. Reports: 2019. 2018. 2017, 2016, 2015, 2014.
8. Survstat . https://survstat.rki.de/Content/Query/Create.aspx . Germany epidemiology data table.
9. Institut Pasteur, Bilan IIM 2017 2018 2099 Santé Publique France, Rapport ECDC Invasive Meningococcal Disease, Recontres Pédiatriques 2020. France epidemiology data table.
10. MenveoTM Summary of Product Characteristics.
11. NimenrixTM Summary of Product Characteristics.
12. DeCoster I, Fournie X, Faure C, et al. Assessment of preparation time with fully liquid versus on fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015;(33):3976 3982.
13. Bröker M, Berti F, Costantino P. Factors contributing to the immunogenicity of meningococcal conjugate vaccines. Hum Vaccin Immunother . 2016; 12(7):1808 1824.
14. van der Vliet D, Vesikari T, Sandner B, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid conjugate vaccine ( MenACYW TT) vs. a licensed quadrivalent meningococcal tetanus toxoid conjugate vaccine in meningococcal vaccine naïve and meningococcal C conjugate vaccine primed toddlers: a phase III randomised study. Epidemiol Infect. 2021;149:e50.
15. Chang LJ, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW TT, in healthy adolescents in the United States. Vaccine. 2020;38(19):3560 3569.
16. Data on file. MET43 Safety.
17. Esteves Jaramillo A, Koehler T, Jeanfreau R, Neveu D, Jordanov E, Singh Dhingra M. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid conjugate vaccine ( MenACYW TT) in ≥56 year olds: A Phase III randomized study. Vaccine. 2020;38(28):4405 4411.